Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Autor: Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

Externí odkaz: https://doaj.org/article/1872bd3c329443328fa10ee0e5e38651

Abstract OT1-18-02: First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial

Autor: Veronique Debien, Christian Maurer, Philippe Aftimos, Florian Clatot, Delphine Loirat, Kevin Punie, François Ghiringhelli, Anhony Gonçalves, Donatienne Taylor, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, François Duhoux, Renaud Poncin, Fernando Bazan, Nicolas Isambert, Philippe Barthelemy, Mariana Brandão, Paulus Kristanto, Michail Ignatiadis, Martine Piccart, Laurence Buisseret

Publikováno v: Cancer Research. 82:OT1-18

Background: Metastatic triple-negative breast cancer (mTNBC) is the most aggressive and heterogeneous breast cancer subtype, with limited therapeutic options. Immune-checkpoint inhibitors (ICI) with chemotherapy are approved as first-line therapy in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce468b29f5b98b267e359f74698e8b97
https://doi.org/10.1158/1538-7445.sabcs21-ot1-18-02

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Autor: Aditya Bardia, Francois-Clement Bidard, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose Angel García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Philippe Aftimos, Javier Cortés, Giulia Tonini, Tarek Sahmoud, Nassir Habboubi, Krzysztof Grzegorzewski, Virginia Kaklamani

Publikováno v: Cancer Research. 83:GS3-01

Background: In patients (pts) with ER+/HER2− metastatic breast cancer (MBC) following progression on prior endocrine and CDK4/6i therapy, the EMERALD trial demonstrated significantly prolonged progression-free survival (PFS) and a manageable safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbaa45271f34c35df8e27971ce271b5c
https://doi.org/10.1158/1538-7445.sabcs22-gs3-01

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Autor: Francois-Clement Bidard, Virginia G. Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José A. García Sáenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia

Publikováno v: Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (28), pp.3246-3256. ⟨10.1200/JCO.22.00338⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, p. JCO2200338 (2022)

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3250d1e4d1eec1c650e6a9b2f6960b1
https://hdl.handle.net/10281/402049

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Autor: Cortes, Javier, Cescon, David W, Rugo, Hope S, Nowecki, Zbigniew, Im, Seock-Ah, Yusof, Mastura Md, Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhao, Jing, Aktan, Gursel, Karantza, Vassiliki, Schmid, Peter, Luis, Fein, Gonzalo, Gomez Abuin, Diego, Kaen, Ruben, Kowalwszyn, Matias, Molina, Mirta, Varela, Sally, Baron-Hay, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Andrea, Gombos, Donatienne, Taylor, Carlos, Barrios, Leandro, Brust, Fabiano, Costa, Ruffo, de Freitas Junior, Roberto, Hegg, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Roberto Odebrecht, Rocha, Antonio Orlando, Scalabrini Neto, Felipe, Silva, David, Cescon, Danielle, Charpentier, Cristiano, Ferrario, Xinni, Song, Joanne, Yu, Alejandro, Acevedo, Carlos, Gallardo, Claudio, Salas, Cesar, Sanchez, Eduardo, Yanez, Alvaro, Gomez Diaz, Jesus, Sanchez, Petra, Holeckova, Zdenek, Kral, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Vesna, Glavicic, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Anthony, Goncalves, Anne-Claire, Hardy-Bessard, Luis, Teixeira, Jens-Uwe, Blohmer, Peter, Fasching, Dirk, Forstmeyer, Nadia, Harbeck, Jens, Huober, Anna, Kaczerowsky Flores de Sousa, Christian, Kurbacher, Sibylle, Loibl, Diana, Lueftner, Tjoung-Won, Park-Simon, Raquel Von, Schumann, Pauline, Wimberger, Louis, Chow, Ava, Kwong, Kai Cheong Roger, Ngan, Peter, Arkosy, Tibor, Csoszi, Zsuzsanna, Kahan, Laszlo, Landherr, Karoly, Mahr, Gabor, Rubovszky, John, Crown, Catherine, Kelly, Seamus, O'Reilly, Saverio, Cinieri, Antonietta, DAlessio, Enrico, Ricevuto, Tomoyuki, Aruga, Takaaki, Fujii, Kenichi, Inoue, Takashi, Ishikawa, Yoshinori, Ito, Tsutomu, Iwasa, Hiroji, Iwata, Yoshimasa, Kosaka, Koji, Matsumoto, Yasuo, Miyoshi, Hirofumi, Mukai, Seigo, Nakamura, Naoki, Niikura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Eiji, Suzuki, Masato, Takahashi, Yuko, Tanabe, Kenji, Tamura, Koichiro, Tsugawa, Junichiro, Watanabe, Naohito, Yamamoto, Yutaka, Yamamoto, Teruo, Yamauchi, Anita, Bustam, Mastura, Md Yusof, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Jorge, Martinez Rodriguez, Flavia, Morales-Vasquez, Jessica, Reyes Contreras, Karin, Beelen, Vivianne, Tjan-Heijnen, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Cezary, Szczylik, Rafal, Tarnawski, Bogdan, Zurawski, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Andrey, Meshcheryakov, Vladimir, Moiseyenko, Guzel, Mukhametshina, Jin Hee, Ahn, Seock-Ah, Im, Keun Seok, Lee, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Josefina, Cruz Jurado, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Esther, Holgado, Esther, Zamora Adelantado, Chien-Ting, Liu, Mei-Ching, Liu, Chiun-Sheng, Huang, Chao-Jung, Tsao, Ling-Ming, Tseng, Cagatay, Arslan, Gul, Basaran, Irfan, Cicin, Erhan, Gokmen, Seyda, Gunduz, Nil, Molinas Mandel, Mustafa, Ozguroglu, Ozgur, Ozyilkan, Sinan, Yavuz, Steve, Chan, Janine, Graham, Iain, MacPherson, Peter, Schmid, Nicholas, Turner, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Hryhoriy, Adamchuk, Oleksandr, Berzoy, Igor, Bondarenko, Oleksii, Kolesnik, Olena, Kolesnik, Hanna, Komisarenko, Anna, Kryzhanivska, Iurii, Leshchenko, Alla, Nasonova, Natalya, Otchenash, Olga, Ponomarova, Andrii, Rusyn, Sergii, Shevnya, Yaroslav, Shparyk, Dmytro, Trukhin, Grygorii, Ursol, Ihor, Vynnychenko, Sibel, Blau, Madhu, Chaudhry, Michael, Chung, Patrick, Cobb, Scott, Cole, Jennifer, Diamond, Keerthi, Gogineni, Jeffrey, Hargis, Kent, Hoskins, William, Irvin, Randa, Loutfi, Janice, Lu, Raul, Mena, Susan, Moore, Rita, Nanda, Ira, Oliff, Coral, Omene, Timothy, Panella, Amit, Panwalkar, Brian, Patson, Hope, Rugo, Irina, Rybalova, Michael, Schleider, Robert, Siegel, Michael, Simon, Laura, Stampleman, Bradley, Sumrall, Michaela, Tsai, Frances, Valdes-Albini

Publikováno v: The Lancet; December 2020, Vol. 396 Issue: 10265 p1817-1828, 12p